Medtronic (NYSE:MDT) today touted results from a study of its 3f Enable replacement heart valve, saying the sutureless aortic valve implant showed a 6% mortality rate after 5 years.
American Assn. for Thoracic Surgery
Valve-in-valve implantation for failed heart valves shows good short-term results
The short-term results of minimally invasive transcatheter valve-in-valve implantation to treat failed biological heart valve protheses are "excellent," but patients must be closely monitored due to some notable cases of suboptimal systolic-valve performance, according to early data from a multi-center trial.